SEC Form SC 13G/A filed by Berkeley Lights Inc. (Amendment)

$BLI
Medicinal Chemicals and Botanical Products
Health Care
Get the next $BLI alert in real time by email
SC 13G/A 1 cell13ga.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. 1)*

 

 

PhenomeX Inc.

(Name of Issuer)

 

 

Common Stock, par value $0.00005 per share

(Title of Class of Securities)

 

 

084310101

(CUSIP Number)

 

 

December 31, 2023

(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

[X]       Rule 13d-1(b)

 

[X]       Rule 13d-1(c)

 

[ ]       Rule 13d-1(d)

 

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 

 1 
CUSIP No. 084310101

 

 

1.Names of Reporting Persons.


Beryl Capital Management LLC

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     X     

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization Delaware

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 0

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 0
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 0%

 

12. Type of Reporting Person (See Instructions) IA, OO

 2 
CUSIP No. 084310101

 

 

1.Names of Reporting Persons.


Beryl Capital Management LP

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     X     

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization Delaware

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 0

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 0
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 0%

 

12. Type of Reporting Person (See Instructions) IA, PN

 3 
CUSIP No. 084310101

 

 

1.Names of Reporting Persons.


Beryl Capital Partners II LP

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a)          

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization Delaware

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 0

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 0
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 0%

 

12. Type of Reporting Person (See Instructions) PN

 4 
CUSIP No. 084310101

 

1.Names of Reporting Persons.


David A. Witkin

 

2.Check the Appropriate Box if a Member of a Group (See Instructions)

(a)     X     

(b) ______

 

3. SEC Use Only

 

4.Citizenship or Place of Organization U.S.A.

 

Number of

Shares

Beneficially

Owned by

Each Reporting

Person With:

5. Sole Voting Power 0

 

6. Shared Voting Power 0

 

7. Sole Dispositive Power 0
8. Shared Dispositive Power 0

 

9.Aggregate Amount Beneficially Owned by Each Reporting Person 0

 

10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
Instructions) ______

 

11.Percent of Class Represented by Amount in Row (9) 0%

 

12. Type of Reporting Person (See Instructions) IN, HC

 5 
CUSIP No. 084310101

Item 1.

 

(a)Name of Issuer

PhenomeX Inc.

 

(b)Address of Issuer's Principal Executive Offices

5858 Horton Street, Suite 320, Emeryville, CA 94608

 

Item 2.

 

(a)The names of the persons filing this statement are:

Beryl Capital Management LLC (“Beryl”), Beryl Capital Management LP (“Beryl GP”), Beryl Capital Partners II LP (the “Partnership”) and David A. Witkin (collectively, the “Filers”). Each Filer disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

 

(b)The principal business office of the Filers is located at:

225 Avenue I, Suite 205, Redondo Beach, CA 90277

 

(c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

 

(d)This statement relates to the Issuer’s Common Stock, par value $0.00005 per share (the "Stock").

 

(e)The CUSIP number of the Issuer is: 084310101

 

 

 6 
CUSIP No. 084310101

 

Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 

(a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

 

(b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

 

(c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

 

(d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

 

(e)[X] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E), as to Beryl and Beryl GP.

 

(f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

 

(g)[X] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G), as to Mr. Witkin.

 

(h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

 

(i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

 

(j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

 

(k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

 

Item 4.Ownership.

 

See Items 5-9 and 11 of the cover page for each Filer.

 

Item 5.Ownership of Five Percent or Less of a Class

 

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X ].

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

 

Not applicable.

 

Item 8.Identification and Classification of Members of the Group.

 

Beryl is the investment adviser to the Funds and other accounts. Beryl is the general partner of Beryl GP, which is the general partner of one or more of the Funds. Mr. Witkin is the control person of Beryl.

 

Item 9.Notice of Dissolution of Group

 

Not applicable.

 

Item 10.Material to Be Filed as Exhibits

Exhibit A Joint Filing Agreement.

Item 11.Certification of Beryl, Beryl GP and Mr. Witkin.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Certification of the Partnership.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

 7 
CUSIP No. 084310101

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: February 8, 2024

 

BERYL CAPITAL MANAGEMENT LLC  

BERYL CAPITAL MANAGEMENT LP

 

      By: Beryl Capital Management LLC
        General Partner
By: /s/ Andrew Nelson      
  Andrew Nelson     By: /s/ Andrew Nelson  
  Chief Operating Officer and CFO       Andrew Nelson  
        Chief Operating Officer and CFO  
BERYL CAPITAL PARTNERS II LP    
     
By: Beryl Capital Management LP   /s/ David A. Witkin
General Partner   David A. Witkin
     
By: Beryl Capital Management LLC    
General Partner    
     
By:/s/ Andrew Nelson    
Andrew Nelson    
Chief Operating Officer    
 8 
CUSIP No. 084310101

 

EXHIBIT A

 

AGREEMENT REGARDING JOINT FILING

OF STATEMENT ON SCHEDULE 13D OR 13G

 

The undersigned agree to file jointly with the Securities and Exchange Commission (the "SEC") any and all statements on Schedule 13D or Schedule 13G and Forms 3, 4 or 5 (and any amendments or supplements thereto) required under section 13(d) or 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Beryl Capital Management, LLC, a Delaware limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

 

 

Dated: February __, 2024

 

BERYL CAPITAL MANAGEMENT LLC  

BERYL CAPITAL MANAGEMENT LP

 

      By: Beryl Capital Management LLC
        General Partner
By: /s/ Andrew Nelson      
  Andrew Nelson     By: /s/ Andrew Nelson  
  Chief Operating Officer and CFO       Andrew Nelson  
        Chief Operating Officer and CFO  
BERYL CAPITAL PARTNERS II LP    
     
By: Beryl Capital Management LP   /s/ David A. Witkin
General Partner   David A. Witkin
     
By: Beryl Capital Management LLC    
General Partner    
     
By:/s/ Andrew Nelson    
Andrew Nelson    
Chief Operating Officer    

 

 

Get the next $BLI alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BLI

DatePrice TargetRatingAnalyst
8/10/2022$10.00 → $5.00Equal-Weight → Underweight
Morgan Stanley
8/10/2022Buy → Neutral
BTIG Research
8/10/2022$12.00 → $8.00Overweight → Neutral
JP Morgan
3/2/2022Outperform
Cowen
2/25/2022$20.00 → $14.00Equal-Weight
Morgan Stanley
2/15/2022$36.00 → $20.00Equal-Weight
Morgan Stanley
1/6/2022$61.00 → $12.00Buy → Hold
Stifel
1/6/2022Outperform → Mkt Perform
William Blair
More analyst ratings

$BLI
Press Releases

Fastest customizable press release news feed in the world

See more
  • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    $CTNM
    $IONS
    $NVS
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products
  • Berkeley Lights Completes Acquisition of IsoPlexis Forming PhenomeX, the Functional Cell Biology Company

    PhenomeX to begin trading under symbol (NASDAQ:CELL) EMERYVILLE, Calif., March 21, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that it has completed its previously announced acquisition of IsoPlexis Corporation (NASDAQ:ISO), a company empowering labs to leverage the cells and proteome changing the course of human health. The newly combined company has been renamed PhenomeX and its common stock will begin trading on Nasdaq under the ticker symbol "CELL" at market open tomorrow. PhenomeX is positioned to be the leading

    $BLI
    $ISO
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

    EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care

$BLI
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BLI
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BLI
SEC Filings

See more

$BLI
Leadership Updates

Live Leadership Updates

See more
  • Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc. (NASDAQ:RNA), as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum's board. Ms. Boyce has extensive expertise in global pharmaceut

    $CTNM
    $IONS
    $NVS
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals
    Medicinal Chemicals and Botanical Products
  • Berkeley Lights Announces Appointment of Scott Chaplin as Chief Legal Officer

    EMERYVILLE, Calif., Sept. 19, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Scott Chaplin has been named the Company's chief legal officer and corporate secretary, effective immediately. Mr. Chaplin will have overall responsibility for the corporate legal function, including contracts, governance, compliance and management of its extensive intellectual property and patent portfolio. As chief legal officer, he will serve as an adviser to the chief executive officer (CEO), Board of Directors, and senior management members.

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
  • Berkeley Lights Announces Appointment of Dr. Rolando Brawer as Executive Vice President, Strategy & Corporate Development

    EMERYVILLE, Calif., Aug. 1, 2022 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced that Rolando Brawer, Ph.D. has been named executive vice president, Strategy & Corporate Development, effective immediately. In this newly created role, Dr. Brawer will lead Berkeley Lights' strategy and corporate development functions and support the Company's growth strategy through identification, assessment and execution of potential mergers, acquisitions, investments, licensing agreements, joint ventures and more. "We are thrilled to welco

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care

$BLI
Financials

Live finance-specific insights

See more
  • Berkeley Lights Reports Fourth Quarter and Full Year 2022 Financial Results

    EMERYVILLE, Calif., Feb. 23, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights Achieved revenue of $78.6 million for the full year 2022, representing an 8% decrease over the prior year;Announced the acquisition agreement of IsoPlexis to create a premier functional cell biology company, PhenomeX, when the merger closes, would accelerate the transformation of Berkeley Lights from a technology platform company into a growing, profi

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
  • Berkeley Lights to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

    EMERYVILLE, Calif., Feb. 13, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced that the Company will be reporting financial results for the fourth quarter and full year 2022 after market on Thursday, February 23, 2023. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   Live audio of the webcast will be available on the "Investors" section of the Company's website at www.berkeleylights.com. The webcast will be archived and available for replay

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care
  • Berkeley Lights Reports Preliminary Full Year 2022 Revenue Results

    EMERYVILLE, Calif., Jan. 9, 2023 /PRNewswire/ -- Berkeley Lights, Inc. (NASDAQ:BLI), a life sciences tools company, today announced preliminary unaudited revenue results for the full year ended December 31, 2022. Total revenue for the full year 2022 is expected to be in the range of $78.0 million to $78.5 million, compared to $85.4 million in 2021. Results were lower-than-expected due to a delay in several Beacon® platform placements, which are now expected in 2023, and lower revenue from partnership and services contracts. During fourth quarter 2022, we observed a tightening

    $BLI
    Medicinal Chemicals and Botanical Products
    Health Care

$BLI
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more